This statistic shows the percentage of the U.S. population with usage of prescription drugs within the past month between 1988 and 2018. In the period 2015-2018, **** percent of the population under 18 years used prescription drugs.

As of 2019, the share of Croatians aged 15 years and older who had used a prescription drug in the past two weeks stood at some 62 percent. Thus, this was the highest percentage among listed European countries. This statistic shows the share of population in European countries using prescription drugs in 2019, based on self-reporting.

This statistic shows the percentage of the total U.S. population using at least one prescription drug in the past month (30 days) in selected time intervals between 1988 and 2018. In the 2015-2018 period, **** percent of the U.S. population used at least one prescription drug within ** days.

This statistic shows the percentage of the total U.S. population using at least one prescription drug within the past month (30 days) in selected time intervals between 1988 and 2018. In the 2015-2018 period, 41.7 percent of the male population used at least one prescription drug within 30 days.

Data Data comes from Organisation for Economic Cooperation and Development on https://data.oecd.org/healthres/pharmaceutical-spending.htm

It consists of useful information about the percent of health spending, percent of GDP and US dollars per capita for specific countries. Also, we added total spending by countries using their population data.

Population data comes from DataHub http://datahub.io/core/population since it is regularly updated and includes all country codes.

Preparation There are several steps that have been done to get the final data.

We extracted separately each resource by “percent of health spending”, “percent of GDP” and “US dollars per capita” We merged them into one resource and added nenew column “TOTAL_SPEND” “TOTAL_SPEND” is calculated using “US dollars per capita” and “population” data. Source for original pharmacy drug spending: https://stats.oecd.org/sdmx-json/data/DP_LIVE/.PHARMAEXP.../OECD?contentType=csv&detail=code&separator=comma&csv-lang=en.

As of July 2023, ** percent of Americans surveyed reported that they currently take **** or more prescription drugs. On the other hand, ** percent of the surveyed stated to take only *** prescription drug at that time.

Medicine Market Outlook

The global medicine market size stood at approximately USD 1.4 trillion in 2023 and is projected to reach a staggering USD 2.5 trillion by 2032, growing at a compound annual growth rate (CAGR) of around 6.5%. This robust growth can be attributed to the increasing prevalence of chronic diseases, advancements in medical technology, and the rising geriatric population worldwide. The demand for innovative medicines and treatments continues to fuel the expansion of the market, further strengthened by government initiatives and increasing healthcare expenditure across the globe. The market is poised for substantial growth over the forecast period, driven by these dynamic factors.

A significant growth factor driving the medicine market is the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer. With a rise in lifestyle-related conditions due to sedentary habits, poor diet, and environmental factors, the demand for medications and treatment options has surged. Moreover, the global aging population is expanding rapidly, which further escalates the need for healthcare solutions. This demographic shift creates a substantial market for medicines aimed at managing chronic conditions prevalent among older adults. Additionally, the ongoing development of personalized medicine and precision healthcare, which tailors treatment to individual genetic profiles, is further propelling market growth.

Advancements in medical technology and drug development processes also significantly bolster the medicine market. Innovations in biotechnology, genomics, and nanotechnology have led to the creation of more effective and targeted therapies. Biologics, in particular, have gained prominence due to their potential to treat previously untreatable conditions. Pharmaceutical companies are investing heavily in research and development to bring new and innovative drugs to market, enhancing therapeutic outcomes and patient quality of life. Furthermore, the adoption of digital technologies and artificial intelligence in drug discovery and development processes is accelerating the time-to-market for new medicines, thereby contributing to market expansion.

Another pivotal factor enhancing the growth of the medicine market is the increase in healthcare spending globally. Governments and private organizations are dedicating more resources to improve healthcare infrastructure, making medicines more accessible to the population. The expansion of healthcare insurance coverage and reimbursement policies in many regions has also made medicines more affordable and accessible to a larger audience. In addition, the rise of telemedicine and online pharmacy platforms is changing the way healthcare is delivered, making it easier for patients to obtain necessary medications. These developments in healthcare systems and services are expected to support sustained growth in the medicine market over the coming years.

Regionally, North America continues to dominate the medicine market due to its well-established healthcare infrastructure and high expenditure on research and development. Europe also holds a significant share, driven by an increasing focus on healthcare innovation and chronic disease management. Meanwhile, the Asia Pacific region is expected to witness the highest growth rate, with a CAGR surpassing 8%, fueled by improving healthcare facilities, economic growth, and a rising middle-class population demanding better healthcare services. Emerging markets in Latin America and the Middle East & Africa are also showing promising growth, albeit at a slower pace, as they continue to develop their healthcare systems and address public health challenges.

Product Type Analysis

In the medicine market, product type plays a crucial role in defining the scope and reach of pharmaceutical companies. Prescription medicines hold the largest share of the market due to their essential role in managing and treating both acute and chronic conditions. These medicines are subject to rigorous regulatory standards and require healthcare professionals' authorization for use, ensuring their efficacy and safety. The demand for prescription medications is driven by the rising incidence of chronic diseases and the need for specialized and long-term treatments. Additionally, the emergence of new therapies and drugs targeting specific health conditions continues to bolster the growth of this segment.

Over-the-counter (OTC) medicines, another critical segment, are gaining considerable traction due to their accessibility and affordability. These medicines, available

About this dataset

Context

The dataset tabulates the Medicine Park population over the last 20 plus years. It lists the population for each year, along with the year on year change in population, as well as the change in percentage terms for each year. The dataset can be utilized to understand the population change of Medicine Park across the last two decades. For example, using this dataset, we can identify if the population is declining or increasing. If there is a change, when the population peaked, or if it is still growing and has not reached its peak. We can also compare the trend with the overall trend of United States population over the same period of time.

Key observations

In 2023, the population of Medicine Park was 461, a 2.90% increase year-by-year from 2022. Previously, in 2022, Medicine Park population was 448, an increase of 3.70% compared to a population of 432 in 2021. Over the last 20 plus years, between 2000 and 2023, population of Medicine Park increased by 57. In this period, the peak population was 461 in the year 2023. The numbers suggest that the population has not reached its peak yet and is showing a trend of further growth. Source: U.S. Census Bureau Population Estimates Program (PEP).

Content

When available, the data consists of estimates from the U.S. Census Bureau Population Estimates Program (PEP).

Data Coverage:

• From 2000 to 2023

Variables / Data Columns

• Year: This column displays the data year (Measured annually and for years 2000 to 2023)
• Population: The population for the specific year for the Medicine Park is shown in this column.
• Year on Year Change: This column displays the change in Medicine Park population for each year compared to the previous year.
• Change in Percent: This column displays the year on year change as a percentage. Please note that the sum of all percentages may not equal one due to rounding of values.

Good to know

Margin of Error

Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.

Custom data

If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.

Inspiration

Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.

Recommended for further research

This dataset is a part of the main dataset for Medicine Park Population by Year. You can refer the same here

About this dataset

Context

The dataset tabulates the Medicine Park population by age cohorts (Children: Under 18 years; Working population: 18-64 years; Senior population: 65 years or more). It lists the population in each age cohort group along with its percentage relative to the total population of Medicine Park. The dataset can be utilized to understand the population distribution across children, working population and senior population for dependency ratio, housing requirements, ageing, migration patterns etc.

Key observations

The largest age group was 18 to 64 years with a poulation of 218 (63.37% of the total population). Source: U.S. Census Bureau American Community Survey (ACS) 2019-2023 5-Year Estimates.

Content

When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2019-2023 5-Year Estimates.

Age cohorts:

• Under 18 years
• 18 to 64 years
• 65 years and over

Variables / Data Columns

• Age Group: This column displays the age cohort for the Medicine Park population analysis. Total expected values are 3 groups ( Children, Working Population and Senior Population).
• Population: The population for the age cohort in Medicine Park is shown in the following column.
• Percent of Total Population: The population as a percent of total population of the Medicine Park is shown in the following column.

Good to know

Margin of Error

Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.

Custom data

If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.

Inspiration

Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.

Recommended for further research

This dataset is a part of the main dataset for Medicine Park Population by Age. You can refer the same here

Pharmaceutical Drugs Market Outlook

The pharmaceutical drugs market size was valued at approximately USD 1.3 trillion in 2023 and is projected to reach around USD 2.0 trillion by 2032, reflecting a compound annual growth rate (CAGR) of 5.1% over the forecast period. This market's expansion can be attributed to several growth factors, including increasing global population, rising prevalence of chronic diseases, and advancements in drug development technologies. The growing investment in healthcare infrastructures and the surge in healthcare expenditure by both private and public sectors are also vital contributors. As countries continue to navigate through global health challenges, the emphasis on pharmaceuticals as a crucial component in healthcare is unwavering, setting the stage for sustained market growth.

One of the critical growth drivers of the pharmaceutical drugs market is the demographic shift towards an aging population. As life expectancy continues to rise, there is an increasing demand for medications that manage age-related diseases such as cardiovascular, neurological, and respiratory conditions. The elderly population is more susceptible to chronic diseases, thus fueling the demand for long-term medications. Furthermore, the rise in lifestyle-related health issues, such as diabetes and hypertension, is propelling the demand for pharmaceutical interventions. These demographic and lifestyle changes necessitate the development of new drugs and the adaptation of existing ones, thereby continuously expanding the market.

Another significant growth factor is the evolution of pharmaceutical technologies and drug development processes. Innovations such as personalized medicine, biotechnology, and gene therapy are transforming the pharmaceutical landscape. Personalized medicine, which tailors treatments to individual genetic profiles, is gaining traction, while biotechnology advancements are leading to the development of biologics that target specific disease mechanisms with higher precision. Additionally, the ongoing research in gene therapy is offering promising treatments for genetic disorders that were previously deemed incurable. These technological advancements are not only broadening the scope of treatment options but also enhancing the efficacy and safety of pharmaceutical drugs.

The increase in healthcare expenditure and supportive government policies worldwide are further propelling the pharmaceutical drugs market. Many governments are implementing policies to streamline drug approval processes and are encouraging innovation through tax credits and funding. The rise in healthcare spending is facilitating improved access to medicines and driving the expansion of healthcare infrastructures, particularly in emerging markets. This increased accessibility is crucial in meeting the demands of growing populations and addressing unmet medical needs, thereby contributing to the market's growth trajectory. Additionally, the pharmaceutical industry is witnessing a surge in strategic collaborations and partnerships, which are pivotal in enhancing research capabilities and expanding market reach.

Regionally, North America continues to dominate the pharmaceutical drugs market, accounting for the largest share due to its advanced healthcare infrastructure, significant R&D investments, and a high prevalence of chronic diseases. Europe follows closely, supported by robust healthcare systems and an emphasis on innovation. Meanwhile, the Asia Pacific region is exhibiting the fastest growth, driven by an expanding population, increasing healthcare awareness, and rising income levels. Countries like China and India are becoming significant players due to their large domestic markets and growing R&D capabilities. Latin America, along with the Middle East and Africa, are also showing promising growth prospects due to improving healthcare access and economic development, albeit at a slower pace compared to other regions.

Drug Type Analysis

The drug type segment of the pharmaceutical market is categorized into branded, generic, and over-the-counter (OTC) drugs. Branded drugs, known for their innovation and high R&D investment, continue to hold a significant portion of the market. These drugs are often the first line of treatment due to their proven efficacy and safety profiles. However, the high costs associated with branded drugs can be a barrier for some patients, which makes the role of generics in the pharmaceutical ecosystem particularly vital. Generics offer similar efficacy at a fraction of the cost, thus providing essential affordability and accessibility in global healthcare settings

The National Prescribed Drug Register provides the basis for the official statistics about prescribed drugs in Sweden.

The National Prescribed Drug Register with personal identity numbers was established in July 2005 and contains all prescribed drugs dispensed at pharmacies. About 67 percent (6.8 million) of the population were prescribed a pharmaceutical at least once 2019. Each row in the register corresponds to one dispensation at a pharmacy. The number of rows in the register amounts to more than 100 million per year. This level has remained almost unchanged for several years.

The purpose of the Swedish Prescribed Drug Register is to increase the patient safety in the pharmaceutical area. The register is used by researchers, media, analysts in the regions and authorities as well as by the pharmaceutical industry. The register can be linked to other health data registers, for example the National Patient Register or the National Medical Birth Register. Increased knowledge of the effects and safety of different drugs may be of benefit to each individual patient in the long run.

The register is updated each month with new data from the Swedish eHealth Agency based on the monthly billing of the pharmacies. The register contains all prescribed drugs that are dispensed at pharmacies as well as information on dispensed medical devices and medical consumables within the pharmaceutical benefits scheme, such as ostomy products and foods for nutritional use by children under 16 years.

Drugs administered at hospital settings or nursing homes are not included in the register. Vaccines and over-the-counter medicines are not included in the register. In the register it is not possible to identify individual prescribers or the individual prescriber’s workplace.

The register contains information about

• patient (gender, age, place of residence)
• product (for example ATC code, drug name, strength, pack size, included/not included in the pharmaceutical benefits scheme)
• the prescription (for example prescribed quantity/number of packages, strength, date of prescription, date of purchase and type of ordination.)
• the costs (total cost, patient cost, region’s cost and additional patient cost)
• the prescriber (work title, kind of care according to the work-place, education code and specialist education code).

For a complete list of all variables see the variable list (xlsx).

Reporting

All data in the National Prescribed Drug Register comes from the Swedish eHealth Agency. Pharmacies, retailers and wholesalers are obligated to report their sales to the Swedish eHealth Agency. In addition, pharmacies must submit additional information to the Swedish eHealth Agency when a prescribed drug is dispensed. The Swedish eHealth Agency in turn submits information on prescription dispensations to the National Board of Health and Welfare.

The quality of the National Prescribed Drug Register is overall very good. The risk of measurement errors is small since the collection process is largely automated and is based on administrative systems. The Swedish eHealth Agency checks the quality of the sales data that the pharmacies deliver before it is included in the register, but errors and incompletions cannot be completely avoided.

A small proportion of the rows in the National Prescribed Drug Register have negative values for the variables antal, tkost, lankost, patkost, merkost and fddd. This is not a lack of quality but rather how the register is corrected. This may be due to the fact that a drug has been registered in the system but has not been retrieved or that a pharmacy has accepted a repurchase of medicines (e.g. in case of product failure). There may also be misreported transactions that need to be corrected for some reason. The minus rows are used for the register to match when aggregating and summing.

Share

About this dataset

Context

The dataset tabulates the Medicine Lodge population over the last 20 plus years. It lists the population for each year, along with the year on year change in population, as well as the change in percentage terms for each year. The dataset can be utilized to understand the population change of Medicine Lodge across the last two decades. For example, using this dataset, we can identify if the population is declining or increasing. If there is a change, when the population peaked, or if it is still growing and has not reached its peak. We can also compare the trend with the overall trend of United States population over the same period of time.

Key observations

In 2023, the population of Medicine Lodge was 1,707, a 1.33% decrease year-by-year from 2022. Previously, in 2022, Medicine Lodge population was 1,730, an increase of 0.52% compared to a population of 1,721 in 2021. Over the last 20 plus years, between 2000 and 2023, population of Medicine Lodge decreased by 496. In this period, the peak population was 2,203 in the year 2000. The numbers suggest that the population has already reached its peak and is showing a trend of decline. Source: U.S. Census Bureau Population Estimates Program (PEP).

Content

When available, the data consists of estimates from the U.S. Census Bureau Population Estimates Program (PEP).

Data Coverage:

• From 2000 to 2023

Variables / Data Columns

• Year: This column displays the data year (Measured annually and for years 2000 to 2023)
• Population: The population for the specific year for the Medicine Lodge is shown in this column.
• Year on Year Change: This column displays the change in Medicine Lodge population for each year compared to the previous year.
• Change in Percent: This column displays the year on year change as a percentage. Please note that the sum of all percentages may not equal one due to rounding of values.

Good to know

Margin of Error

Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.

Custom data

If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.

Inspiration

Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.

Recommended for further research

This dataset is a part of the main dataset for Medicine Lodge Population by Year. You can refer the same here

The U.S. Pharmaceutical Market size was valued at USD 4.1 billion in 2023 and is projected to reach USD 5.96 billion by 2032, exhibiting a CAGR of 5.48 % during the forecasts period. The U. S Pharmaceutical Industry therefore concerns the manufacturing and marketing of medicines and other therapeutic commodities. This sector is the one able to control, treat or even avoid illnesses and contributes to the improvement of health of the population. They are prescription drugs, over-the-counter drugs as well as biologics. There is an emerging pattern of personalized medicine evident in the increase of genomic and biotechnology plus digital health technologies such as telemedicine, health apps. It is also seeing some growth in areas such as specialty drugs and generics with large amounts being spent on research and development to meet the chronic disease and new health ailments. Global factors are also coming into play in this respect including changes in regulations and problems with pricing. Recent developments include: In December 2023, Pfizer received all regulatory approvals for the acquisition of Seagen. This initiative aims to bring commercial changes in the organization thereby creating a new space, the Pfizer Oncology Division to integrate oncology commercial and R&D operations from both the companies. , In January 2023, Sun Pharma announced the launch of a new drug, SEZABY for treating neonatal seizures in the U.S. This is the first USFDA-approved drug for term and pre-term babies. .

The global prescription medicine market size is projected to reach USD XX million by 2033, exhibiting a CAGR of XX% during the forecast period. The growing prevalence of chronic diseases, aging population, and advancements in drug development are driving market growth. Moreover, the increasing disposable income and healthcare spending in developing countries are contributing to the market expansion. The increasing demand for original brand drugs and generic drugs is segmenting the market. Original brand drugs are patented medicines that are protected from competition, while generic drugs are similar versions of original brand drugs with the same active ingredients. The market is dominated by large pharmaceutical companies such as Pfizer, Roche, Novartis, Johnson & Johnson, and Merck & Co. These companies have a strong portfolio of prescription medicines and invest heavily in research and development. North America holds the largest market share, followed by Europe and Asia Pacific. The growing healthcare expenditure in developed regions and the increasing awareness of healthcare in developing regions are contributing to regional market growth.

About this dataset

Context

The dataset tabulates the Yellow Medicine County population over the last 20 plus years. It lists the population for each year, along with the year on year change in population, as well as the change in percentage terms for each year. The dataset can be utilized to understand the population change of Yellow Medicine County across the last two decades. For example, using this dataset, we can identify if the population is declining or increasing. If there is a change, when the population peaked, or if it is still growing and has not reached its peak. We can also compare the trend with the overall trend of United States population over the same period of time.

Key observations

In 2023, the population of Yellow Medicine County was 9,467, a 0.18% decrease year-by-year from 2022. Previously, in 2022, Yellow Medicine County population was 9,484, an increase of 0.48% compared to a population of 9,439 in 2021. Over the last 20 plus years, between 2000 and 2023, population of Yellow Medicine County decreased by 1,731. In this period, the peak population was 11,198 in the year 2000. The numbers suggest that the population has already reached its peak and is showing a trend of decline. Source: U.S. Census Bureau Population Estimates Program (PEP).

Content

When available, the data consists of estimates from the U.S. Census Bureau Population Estimates Program (PEP).

Data Coverage:

• From 2000 to 2023

Variables / Data Columns

• Year: This column displays the data year (Measured annually and for years 2000 to 2023)
• Population: The population for the specific year for the Yellow Medicine County is shown in this column.
• Year on Year Change: This column displays the change in Yellow Medicine County population for each year compared to the previous year.
• Change in Percent: This column displays the year on year change as a percentage. Please note that the sum of all percentages may not equal one due to rounding of values.

Good to know

Margin of Error

Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.

Custom data

If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.

Inspiration

Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.

Recommended for further research

This dataset is a part of the main dataset for Yellow Medicine County Population by Year. You can refer the same here

This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands. Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.

Data are broken down by medicine group, origin, age and sex.

Data available from 2020

Status of the figures: Figures for 2022 are provisional, figures for previous years are final.

Changes as of December 18, 2024: - Provisional figures for 2023 have been added, provisional figures of 2022 have been made definite.

When will new figures be published? New figures will be published in the last quarter of 2025.

The Japan pharmaceutical market, valued at ¥95 billion in 2025, exhibits a moderate growth trajectory with a Compound Annual Growth Rate (CAGR) of 0.92% projected from 2025 to 2033. This relatively low CAGR suggests a mature market characterized by price pressures, stringent regulatory environments, and a focus on innovative therapies. Key drivers include an aging population leading to increased demand for chronic disease treatments, a robust healthcare infrastructure, and ongoing investments in research and development by domestic and international pharmaceutical companies. However, restraints include cost containment measures implemented by the Japanese government, price erosion due to the introduction of generics, and a challenging regulatory approval process. Market segmentation reveals a diverse landscape, with significant contributions from therapeutic areas such as cardiovascular, oncology, and respiratory medications. The prescription drug market, encompassing both branded and generic medications, constitutes a larger portion compared to the Over-The-Counter (OTC) segment. Major players such as Takeda, Astellas, and Daiichi Sankyo dominate the market, leveraging their strong domestic presence and established distribution networks. Future growth will likely be driven by advancements in innovative drug development, particularly in areas like immunotherapy and targeted therapies, as well as increasing adoption of biosimilars. The competitive landscape is intensely competitive, with both established Japanese pharmaceutical companies and multinational corporations vying for market share. Success hinges on strategic partnerships, efficient manufacturing capabilities, and strong regulatory compliance. Furthermore, an increasing focus on personalized medicine and digital health technologies presents both opportunities and challenges for market participants. The market’s evolution will be shaped by government policies aimed at improving access to affordable medications, encouraging innovation, and managing healthcare costs. Companies need to proactively adapt to these shifting dynamics to maintain their market position and achieve sustainable growth. The overall market outlook is one of steady, albeit moderate, expansion, driven by underlying demographic trends and technological advancements within the pharmaceutical industry. Recent developments include: July 2024: Chugai Pharmaceutical Co. Ltd signed an in-licensing agreement with F. Hoffmann-La Roche for in-licensing in vitro PI3Kα inhibitor involisib for the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer with PIK3CA gene mutations. This agreement granted Chugai exclusive development and commercialization rights for involisib in Japan.January 2024: The Japanese Ministry of Health, Labour and Welfare (MHLW) approved the new Eylea 8 mg (aflibercept 8 mg) for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) based on positive results from clinical trials PULSAR and PHOTON.. Key drivers for this market are: Increasing Burden of Chronic Diseases and the Aging Population, Increasing R&D Activities in the Country. Potential restraints include: Increasing Burden of Chronic Diseases and the Aging Population, Increasing R&D Activities in the Country. Notable trends are: The Branded Drugs Sub-Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

This statistic shows the percentage of the U.S. population using five or more prescription drugs within the past month (30 days) in selected periods between 1988 and 2018, by age group. In the 2015-2018 period, almost 42 percent of the U.S. population aged 65 years and over had five or more drug prescriptions within 30 days.

This data package contains the information on the number of beneficiaries of the different types of Medicare Part D Plan with prescription drug coverage, number of prescription drug plans that are eligible for low income subsidy, percent of Medicare Part D Beneficiaries that are eligible, number of prescription drug plans available per region, percent of Medicare population enrolled in the Stand Alone Prescription Drug Plan.